Mitochondrial protection by the mixed muscarinic/sigma-1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Ab25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model. January 20, 2015
Anavex Doses First Alzheimer’s Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS January 12, 2015
Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction with Cannabinoid Receptor January 6, 2015
Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS December 16, 2014
A Phase 1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX 2-73 in Healthy Male Subjects. December 11, 2014
Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’s November 17, 2014
Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference November 10, 2014
